急性低氧性呼吸衰竭与ARDS患者中的叹息通气:PROTECTION初步随机临床试验
BACKGROUND: Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant.…
要点
- 叹息通气在急性低氧性呼吸衰竭或ARDS插管患者中可行,辅助通气失败比例非劣效于单纯PSV。
- 叹息通气前7天氧合改善,潮气量、呼吸频率和校正分钟通气量更低。
核心结论
- 在低氧性插管ICU患者中,应用叹息通气是可行的且不增加风险。
研究设计与样本
- 患者随机分为无叹息组(单纯PSV)和叹息组(PSV加叹息:气道压升至30 cm H2O持续3秒,每分钟1次),直至第28天或死亡或成功自主呼吸试验。
- 主要终点为可行性,以辅助通气失败比例的非劣效性评估(5%容差)。
主要发现
- 随机后前7天叹息组氧合改善,潮气量、呼吸频率和校正分钟通气量更低。
临床怎么用
- 对急性低氧性呼吸衰竭或ARDS插管接受PSV的患者,可考虑应用叹息通气(气道压升至30 cm H2O持续3秒,每分钟1次)作为辅助策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant. RESEARCH QUESTION: Is the clinical application of sigh during pressure support ventilation (PSV) feasible? STUDY DESIGN AND METHODS: We conducted a multicenter noninferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or ARDS undergoing PSV. Patients were randomized to the no-sigh group and treated by PSV alone, or to the sigh group, treated by PSV plus sigh (increase in airway pressure to 30 cm H2O for 3 s once per minute) until day 28 or death or successful spontaneous breathing trial. The primary end point of the study was feasibility, assessed as noninferiority (5% tolerance) in the proportion of patients failing assisted ventilation. Secondary outcomes included safety, physiologic parameters in the first week from randomization, 28-day mortality, and ventilator-free days. RESULTS: Two-hundred and fifty-eight patients (31% women; median age, 65 [54-75] years) were enrolled. In the sigh group, 23% of patients failed to remain on assisted ventilation vs 30% in the no-sigh group (absolute difference, -7%; 95% CI, -18% to 4%; P = .015 for noninferiority). Adverse events occurred in 12% vs 13% in the sigh vs no-sigh group (P = .852). Oxygenation was improved whereas tidal volume, respiratory rate, and corrected minute ventilation were lower over the first 7 days from randomization in the sigh vs no-sigh group. There was no significant difference in terms of mortality (16% vs 21%; P = .337) and ventilator-free days (22 [7-26] vs 22 [3-25] days; P = .300) for the sigh vs no-sigh group. INTERPRETATION: Among hypoxemic intubated ICU patients, application of sigh was feasible and without increased risk. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03201263; URL: www.clinicaltrials.gov.
引用
- Mauri T, Foti G, Fornari C, et al. Sigh in Patients With Acute Hypoxemic Respiratory Failure and ARDS: The PROTECTION Pilot Randomized Clinical Trial. Chest. 2020. PMID: 33197403. doi:10.1016/j.chest.2020.10.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。